Fierce Biotech News & Reports
Dec 18, 2024 · Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on Fierce Biotech as their must-read source for the latest news, analysis and data in the world of biotech ...
A look at the R&D landscape in obesity, led by GLP-1s - Fierce …
Mar 19, 2024 · If you’re feeling like overnight obesity became the indication du jour, you’re not alone. Novo Nordisk was granted approval for semaglutide to be marketed as Wegovy for chronic weight ...
Alcon’s $770M Aerie takeover delivers phase 3 dry eye wins
Jan 10, 2024 · Alcon’s $770 million takeover of Aerie Pharmaceuticals has delivered an early win. The lead candidate in the acquired pipeline met the primary endpoint in a pair of phase 3 dry eye trials ...
Bristol Myers pays $800M upfront for antibody-drug conjugate
Dec 12, 2023 · Bristol Myers Squibb has filled the antibody-drug conjugate (ADC) shaped hole in its pipeline by following the increasingly well-trodden path to China, handing SystImmune $800 million upfront for ...
Genentech inks $850M upfront deal for Regor's CDK inhibitors
Sep 30, 2024 · Genentech is paying $850 million upfront for Regor Pharmaceuticals’ portfolio of CDK inhibitors, taking ownership of a breast cancer candidate that has shown signs of single-agent efficacy in ...
Biotech | Fierce Biotech
Oct 28, 2024 · Since the biotech shared the phase 3 data this morning, the company’s stock has dropped 54%, from $2 per share to 92 cents.
Relay breast cancer data tee up clash with AstraZeneca's Truqap
Sep 9, 2024 · Relay Therapeutics has beaten its survival goal in a first-in-human breast cancer study, positioning the biotech to move into a pivotal trial that could establish its candidate as a challenger to ...
Adaptimmune cell therapy hits key goal in pivotal sarcoma study
Nov 13, 2024 · Adaptimmune Therapeutics is prepping for another FDA submission after 42% of patients with sarcoma responded to the company's investigational cell therapy in a pivotal phase 2 trial.
2seventy splits again, sending cell therapy R&D to Regeneron
Jan 30, 2024 · An earlier version of this story was based on a conference call that was erroneously linked to today's news release. Fierce Biotech has rewritten this story in its entirety as of 2:27 p.m. ET.
Amgen axes an obesity asset, zooms in on MariTide - Fierce Biotech
May 2, 2024 · Amgen is axing obesity candidate AMG 786 and going all in on later-stage asset MariTide. “Given the profile we've seen with AMG 786, we will not pursue further development,” Jay Bradner, M.D ...